ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
Anti-CD20 monoclonal antibody
Immunoglobulin G1, anti-(human CD20 (antigen))(human monoclonal HuMax-CD20 heavy chain), disulfide with human monoclonal HuMax-CD20 kappa-chain, dimer (WHO )
- Ofatumumabum (Latin)
- Ofatumumab (German)
- Ofatumumab (French)
- Ofatumumab (Spanish)
- Ofatumumab (OS: BAN, USAN)
- Ofatumumab (Genetical Recombination) (OS: JAN)
- 2F2 (IS)
- GSK-1841157 (IS)
- HuMax-CD20 (IS)
- UNII-M95KG522R0 (IS)
Glaxo Group, Austria; Glaxo Group, Iceland; Glaxo Group, Lithuania; Glaxo Group, Poland; Glaxo Group, Romania; Glaxo Group Limited-GB, Italy; GlaxoSmithKline, Canada; GlaxoSmithKline, Czech Republic; GlaxoSmithKline, Germany; GlaxoSmithKline, Denmark; GlaxoSmithKline, Spain; GlaxoSmithKline, Finland; GlaxoSmithKline, Greece; GlaxoSmithKline, Croatia (Hrvatska); GlaxoSmithKline, Hungary; GlaxoSmithKline, Ireland; GlaxoSmithKline, Israel; GlaxoSmithKline, Japan; GlaxoSmithKline, Norway; GlaxoSmithKline, Sweden; GlaxoSmithKline, Singapore; GlaxoSmithKline, Slovakia; GlaxoSmithKline UK, United Kingdom; Novartis, France; Novartis, United States; Novartis Pharma, Switzerland; Wellcome Limited, Bosnia & Herzegowina
|BAN||British Approved Name|
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.